<DOC>
	<DOCNO>NCT02878538</DOCNO>
	<brief_summary>The investigator propose conduct series N One ( No1 ) single blind clinical trial pilot feasibility use iron-chelator deferiprone Mild Cognitive Impairment ( MCI ) . Chelation therapy previously report slow rate cognitive decline Alzheimer 's Disease ( AD ) 50 % single human randomize clinical trial .</brief_summary>
	<brief_title>A Pilot Feasibility Using Iron-Chelator Deferiprone Mild Cognitive Impairment</brief_title>
	<detailed_description>Iron chelation 's mechanism action ( MOA ) Alzheimer 's disease ( AD ) uncertain . Potential MOA include reversal aluminum ( AL ) toxicity , prevention a-beta aggregation , β-amyloid disaggregation , obstruction microbacterial viral parasitism . The latter mechanism involve augmentation innate immunity , disruption microbacterial iron metabolism . Infectious model AD 's pathophysiology recently propose . Iron block toll-like receptor ( TLR ) initiate anti-microbial action mediate via gamma-interferon ( IFN-γ ) tumor necrosis factor alpha ( TNF-alpha ) , interleukin-6 ( IL-6 ) , interleukin-10 ( IL-10 ) . These biomarkers interest also associate novel latent dementia phenotype ( i.e. , `` '' `` dementia '' ) Texas Alzheimer 's Research Care Consortium ( TARCC ) . `` '' continuous measure dementia severity construct cognitive battery also include measure Instrumental Activities Daily Living ( IADL ) . Serum biomarkers might `` trigger '' dementing process without participate late stage . Thus , investigator indication might benefit iron-chelation intervention might best apply . This knowledge may help detect effect deferiprone prospective change `` '' even MCI conversion TARCC NHW ( Non Hispanic White ) subject .</detailed_description>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Deferiprone</mesh_term>
	<mesh_term>Chelating Agents</mesh_term>
	<criteria>1 . MA ( Mexican Americans ) NHW TARCC participant competent informant ; 2 . TARCC diagnosis `` MCI '' ( subtype ) ; 3 . Incident MCI conversion MCI control two previous TARCC wave ; 4 . 6580 yrs age ; 5 . Noninstitutionalized level care ; 6 . Capacity give inform consent 7 . GDS ( Geriatric Depression Screen ) score ( 15 item ) ≤ 6 ; 8 . TARCC MMSE ( MiniMental State Examination ) ≥ 26 /30 ; 9 . HIS ( Hachinski Ischemic Scale ) ≤ 05/15 ; 10 . Most recent TARCC dEQscore = 0 ± 0.25 . 1 . A clinical diagnosis `` Diabetes Mellitus '' current treatment insulin ; 2 . A selfreported diagnosis `` Major Depression '' ( treatment `` antidepressant '' exclusionary ) ; 3 . A history psychosis , include visual hallucination ; 4 . History treatment Parkinson 's , tremor , Rapid Eye Movement ( REM ) behavior disorder ; 5 . History treatment atrial fibrillation ; 6 . Treatment cancer last 5 year ( exc . skin cancer ) ; 7 . Major surgery last year ; 8 . History craniotomy ; 9 . Serum Ferritin &lt; 500mcg/ml , Hgb &lt; 14g/dl♂ /12g/dl♀ , , HCT &lt; 45 % ♂ /40 % ♀ , recent blood transfusion ( last 5 year ) , FeSO4 supplementation , erythromycin therapy ; 10 . ANC ( absolute neutrophil count ) &lt; 500 cells/µL , platelet count &lt; 150 × 106 /ml ; 11 . Treatment anticonvulsant , mood stabilizer , neuroleptic , opiate , muscle relaxant , systemic steroid , ADindicated agent .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>